| Basics |
Axon Holdings S.A.
Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia.
|
| IPO Date: |
June 11, 2015 |
| Sector: |
Industrials |
| Industry: |
Aerospace and Defense |
| Market Cap: |
$57.18B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$2.76 | 2.42%
|
| Avg Daily Range (30 D): |
$13.49 | 1.72%
|
| Avg Daily Range (90 D): |
$12.04 | 1.59%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.6M |
| Avg Daily Volume (30 D): |
.51M |
| Avg Daily Volume (90 D): |
.46M |
| Trade Size |
| Avg Trade Size (Sh.): |
73 |
| Avg Trade Size (Sh.) (30 D): |
19 |
| Avg Trade Size (Sh.) (90 D): |
19 |
| Institutional Trades |
| Total Inst.Trades: |
3,236 |
| Avg Inst. Trade: |
$14.82M |
| Avg Inst. Trade (30 D): |
$34.83M |
| Avg Inst. Trade (90 D): |
$36.94M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$25.46M |
| Avg Closing Trade (30 D): |
$58.75M |
| Avg Closing Trade (90 D): |
$64.97M |
| Avg Closing Volume: |
84.87K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
|
$.46
|
$1.14
|
|
Diluted EPS
|
|
$.44
|
$1.08
|
|
Revenue
|
$
|
$ 668.54M
|
$ 603.63M
|
|
Gross Profit
|
$
|
$ 403.74M
|
$ 365.74M
|
|
Net Income / Loss
|
$
|
$ 36.12M
|
$ 87.98M
|
|
Operating Income / Loss
|
$
|
$ -1.04M
|
$ -8.79M
|
|
Cost of Revenue
|
$
|
$ 264.8M
|
$ 237.89M
|
|
Net Cash Flow
|
$
|
$ -477.3M
|
$ 638M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Sep 28, 2007:
1:600
|
|
Nov 30, 2004:
2:1
|
|
Apr 30, 2004:
2:1
|
|
Feb 11, 2004:
3:1
|
|
|
|
